Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction

Clinical Research in Cardiology

Volumn 101, Issue 2, 2012, Pages 117-124

  Desch, Steffen ^a   Siegemund, Annelie ^b   Scholz, Ute ^b   Adam, Natalie ^b   Eitel, Ingo ^a   De Waha, Suzanne ^a   Fürnau, Georg ^a   Lurz, Philipp ^a   Wetzel, Sabrina ^a   Schuler, Gerhard ^a   Thiele, Holger ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MVZ Labor Dr Reising Ackermann und Kollegen   (Germany)

Author keywords

Abciximab; Coronary sinus; Intracoronary; Myocardial infarction; Platelet inhibition

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IIIA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; INTRACORONARY INFUSION; MALE; RECEPTOR OCCUPANCY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CORONARY ANGIOGRAPHY; CORONARY SINUS; FEMALE; FEMORAL VEIN; GERMANY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME;

EID: 84858082745     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-011-0372-6     Document Type: Article

References (26)

1. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120(22):2271-2306. doi:10.1161/CIRCULATIONAHA.109.192663
2. Hansen PR, Iversen A, Abdulla J (2010) Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol 22(6):278-282
3. Schulz S, Birkmeier KA, Ndrepepa G, Moshage W, Dotzer F, Huber K, Dirschinger J, Seyfarth M, Schomig A, Kastrati A, Mehilli J (2010) One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clin Res Cardiol 99(12):795-802. doi:10.1007/s00392- 010-0185-z
4. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP (2004) Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 62(2):186-192. doi:10.1002/ccd.20041 (Pubitemid 38788695)
5. Eitel I, Friedenberger J, Fuernau G, Dumjahn A, Desch S, Schuler G, Thiele H (2011) Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function : The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI). Clin Res Cardiol 100(5):425-432. doi:10.1007/s00392-010- 0260-5
6. Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ (2010) Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 122(25):2709-2717. doi:10.1161/ CIRCULATIONAHA.110.002741
7. Thiele H, Schindler K, Friedenberger J, Eitel I, Furnau G, Grebe E, Erbs S, Linke A, Mobius-Winkler S, Kivelitz D, Schuler G (2008) Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118(1):49-57. doi:10.1161/CIRCULATIONAHA.107.747642
8. Thiele H, Wohrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuehlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G (2010) Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Am Heart J 159(4):547-554. doi:10.1016/j.ahj.2009.12.038
9. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, Kastrati A, von Beckerath N (2008) Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 99(1):121-126. doi: 10.1160/TH07-07-0478
10. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53(10): 849-856. doi:10.1016/j.jacc.2008.11.030
11. Toth O, Calatzis A, Penz S, Losonczy H, Siess W (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96(6):781-788 pii: 06120781 (Pubitemid 44883819)
12. Seyfarth HJ, Koksch M (2004) Fibrinogen receptor antagonists induce conformational changes of the human platelet glycoprotein IIb. Cytometry B Clin Cytom 62(1):14-24. doi:10.1002/cyto.b.20026 (Pubitemid 39463697)
13. Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM (2010) Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation 121(6):784-791. doi: 10.1161/CIRCULATIONAHA.109.882746
14. Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria C (2001) Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 21(1):142-148 (Pubitemid 32061939)
15. Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL (2002) An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 87(6):1020-1025 (Pubitemid 34624885)
16. Cox AD, Devine DV (1994) Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 83(4):1006-1016 (Pubitemid 24058550)
17. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F (2007) Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 23(1):57-63. doi:10.1007/s11239-006-9000-0
18. Mehilli J, Kastrati A, Schulz S, Frungel S, Nekolla SG, Moshage W, Dotzer F, Huber K, Pache J, Dirschinger J, Seyfarth M, Martinoff S, Schwaiger M, Schomig A (2009) Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119(14):1933-1940. doi:10.1161/CIRCULATIONAHA.108. 818617
19. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358(21):2218-2230. doi:10.1056/NEJMoa0708191 (Pubitemid 351724451)
20. Van't Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C (2008) Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372(9638):537-546. doi:10.1016/S0140-6736(08)61235-0
21. Saraf S, Ong PJ, Gorog DA (2008) ClearWay RX - rapid exchange therapeutic perfusion catheter. EuroIntervention 3(5): 639-642 pii: EIJV3I5A114
22. Prati F, Capodanno D, Pawlowski T, Ramazzotti V, Albertucci M, La Manna A, Di Salvo M, Gil RJ, Tamburino C (2010) Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv 3(9):928-934. doi:10.1016/j.jcin.2010.05.017
23. Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW (2011) Rationale and design of the INFUSE-AMI study: a 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. Am Heart J 161 (3):478-486 e477. doi:10.1016/j.ahj.2010.10.006
24. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12):919-933. doi:10.1016/j.jacc.2010.04.047
25. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, stratification. Am J Kidney Dis 39(1):S1-S266 pii: S0272638602093563
26. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E (2001) Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 103(21):2550-2554 (Pubitemid 32521963)